News
02-23-2010, 02:12 AM
Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone.
More... (http://www.news-medical.net/news/20100223/Genentechs-Avastin-combination-Phase-III-study-in-advanced-stomach-cancer-does-not-meet-primary-endpoint.aspx)
More... (http://www.news-medical.net/news/20100223/Genentechs-Avastin-combination-Phase-III-study-in-advanced-stomach-cancer-does-not-meet-primary-endpoint.aspx)